ReviewSexual medicine2013
Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women.
Review in Sexual medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global Prevalence of Overactive Bladder: A Systematic Review and Meta-analysis.International urogynecology journal · 2025Pooled it
- Effects of non-ablative Er:YAG laser on the skin and the vaginal wall: systematic review of the clinical and experimental literature.International urogynecology journal · 2020Pooled it
- Low-Intensity Extracorporeal Shock Wave Therapy Promotes Bladder Regeneration and Improves Overactive Bladder Induced by Ovarian Hormone Deficiency from Rat Animal Model to Human Clinical Trial.International journal of molecular sciences · 2021Trial
- Vitamin E as alternative local treatment in genitourinary syndrome of menopause: a randomized controlled trial.International urogynecology journal · 2019Trial
- Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.Climacteric : the journal of the International Menopause Society · 2016Trial
- The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.Climacteric : the journal of the International Menopause Society · 2015Trial
- Review
- Rose Stem Cell-Derived Exosome-Hyaluronic Acid Therapy for Recurrent Atrophic Vaginitis: A Case Report.Cureus · 2026Article
- Article
- Development of a Vaginal Extracellular Matrix Hydrogel for Combating Genitourinary Syndrome of Menopause.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Switch-like gene expression modulates disease risk.Nature communications · 2025Article
- Locally administered nanosuspension increases delivery of estradiol for the treatment of vaginal atrophy in mice.Drug delivery and translational research · 2025Article
- Untargeted Metabolomics Analysis of Vaginal Secretion Reveals Potential Pathogenesis of Atrophic Vaginitis.Current pharmaceutical design · 2025Article
- Antimicrobial Peptide LCN2 Inhibited UropathogenicInternational journal of molecular sciences · 2022Article
- RNase 7 Inhibits UropathogenicInternational journal of molecular sciences · 2022Article
- Insulin Downregulated the Infection of UropathogenicMicroorganisms · 2021Article
- Nocturia through the menopausal transition and beyond: a narrative review.International urogynecology journal · 2021Review
- Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies.Drugs in context · 2020Article
- Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials.Journal of menopausal medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVaginal atrophy, which may affect up to 45% of postmenopausal women, is often associated with one or more urinary symptoms, including urgency, increased frequency, nocturia, dysuria, incontinence, and recurrent urinary tract infection.
aimsTo provide an overview of the current literature regarding cellular and clinical aspects of vaginal atrophy and response to treatment with local vaginal estrogen therapy.
methodsPubMed searches through February 2012 were conducted using the terms "vaginal atrophy," "atrophic vaginitis," and "vulvovaginal atrophy." Expert opinion was based on review of the relevant scientific and medical literature.
main outcome measureGenitourinary symptoms and treatment of vaginal atrophy from peer-reviewed published literature.
resultsTypically, a diagnosis of vaginal atrophy is made based on patient-reported symptoms, including genitourinary symptoms, and an examination that reveals signs of the disorder; however, many women are hesitant to report vaginal-related symptoms, primarily because of embarrassment.
conclusionsPhysicians in various disciplines are encouraged to initiate open discussions about vulvovaginal health with postmenopausal women, including recommended treatment options. Goldstein I, Dicks B, Kim NN, and Hartzell R. Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women. Sex Med 2013;1:44-53.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.